What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class I recall involving a specific intravenous fluid product manufactured by B. Braun Medical, Inc., a prominent medical supply company based in Bethlehem, Pennsylvania. This action targets a single lot of Lactated Ringer's Injection USP, packaged in 1000 mL EXCEL containers. These are sterile, prescription-only solutions typically used in hospital settings to replace fluids and electrolytes lost due to trauma, surgery, or other medical conditions that cause dehydration or shock. The specific item identified for recall is designated by the National Drug Code (NDC) number 0264-7750-00. It is crucial to note that this recall does not affect all B. Braun products or even all lots of Lactated Ringer's Injection; it is strictly limited to the precise batch details outlined below.
To help healthcare providers and patients identify the affected inventory, the FDA has provided detailed lot information. The recall applies exclusively to Lot number J4H077. This specific lot carries an expiration date of November 30, 2026 (30NOV2026). Because intravenous fluids are critical components of patient care, accurate identification is vital to prevent any potential adverse events. If you or your healthcare provider have this product in stock, it must be removed from use immediately. The product description on the label reads: "Lactated Ringer's Injection USP, 1000 mL EXCEL container, Rx only, L7500, B. Braun Medical, Inc., Bethlehem, PA 18018-3524 USA."
The distribution pattern for this recalled item was nationwide across the United States. This means that hospitals, clinics, pharmacies, and other medical facilities in all states could potentially have received these units. The recall was initiated on August 12, 2026. As a Class I recall, it represents the most serious category of FDA classification, indicating that there is a reasonable probability that the use of this product will cause serious adverse health consequences or death. Therefore, verifying whether your facility possesses NDC 0264-7750-00 from Lot J4H077 is an urgent priority for patient safety.
The hazard, explained
At the heart of this FDA Class I recall is a seemingly simple but potentially serious defect: the presence of particulate matter within the Lactated Ringer’s Injection USP. To understand why this matters, it helps to look at what these fluids are designed to do and how they interact with the human body. Lactated Ringer’s is an intravenous (IV) solution used to restore fluid balance, replace electrolytes, and maintain blood pressure in patients who cannot drink or take nutrients by mouth. It is a sterile, clear liquid intended to flow freely through narrow IV tubing and enter directly into the bloodstream. When foreign particles are introduced into that fluid, they disrupt this critical function, turning a life-sustaining treatment into a potential source of injury.
Particulate matter in an IV bag can take many forms. It might be microscopic glass shards from the manufacturing process or the filling equipment, tiny rubber fragments from stoppers or tubing, fibers from packaging materials, or even crystallized drug precipitates that formed due to temperature fluctuations or chemical incompatibility. In the case of this specific recall by B. Braun Medical Inc., the FDA investigation confirmed that these unapproved particles are present in the affected lots. While the human body has mechanisms to filter out very small particles, larger or numerous particulates can bypass these natural defenses, especially when injected directly into a vein rather than absorbed through the digestive system.
The mechanism of harm occurs when these particles travel with the blood flow. If the particles are large enough, they can physically block small blood vessels, a condition known as embolism. When this happens in the lungs, it can cause pulmonary emboli, leading to difficulty breathing, chest pain, or even respiratory failure. In the brain, blocked vessels can lead to strokes or transient ischemic attacks. Even smaller particles that do not cause immediate blockages can trigger severe inflammatory responses. The body recognizes these foreign objects as threats and mounts an immune reaction, which can result in fever, chills, organ damage, or a condition called granulomatosis, where the body forms tiny nodules around the embedded particles.
This is why the FDA has classified this recall as Class I, the most serious category. A Class I classification indicates that there is a reasonable probability that the use of the product will cause serious adverse health consequences or death. Unlike a minor labeling error, the presence of particulates in an IV solution poses an immediate physical threat because it bypasses the body’s primary barriers to infection and filtration. The risk is not just theoretical; medical professionals have reported incidents related to similar defects in the past, including vascular occlusions and severe inflammatory reactions. Understanding this mechanism underscores why prompt identification and removal of these specific bags from circulation is critical for patient safety.
Who is most at risk
To understand who faces the greatest danger from this recall, we first need to look at how Lactated Ringer’s Injection is used in a medical setting. This is not a product you will find on a household shelf or use for home remedies. It is an intravenous (IV) fluid prescribed by healthcare professionals and administered strictly in clinical environments such as hospitals, surgical centers, and emergency rooms. Therefore, the "ownership" of this specific item lies primarily with medical institutions and pharmacies rather than individual consumers. The individuals directly exposed to the risk are those currently receiving IV therapy through a B. Braun Medical EXCEL container lot J4H077.
The primary group at risk consists of patients who require fluid resuscitation or electrolyte replacement. Lactated Ringer’s is commonly used to treat dehydration, acidosis, and blood loss. Consequently, the people most vulnerable to the consequences of particulate matter in this solution are those who are already critically ill or undergoing major medical procedures. This includes patients in intensive care units, individuals recovering from surgery, and those with severe trauma. Because these patients often have compromised immune systems or open wounds, their bodies are less equipped to handle unexpected foreign substances entering the bloodstream compared to a healthy individual.
While particulate matter can pose risks to any patient receiving an IV infusion, certain subgroups face heightened vulnerability. Elderly patients, for example, often have more fragile blood vessels and reduced kidney function, making it harder for their bodies to filter out microscopic particles. Similarly, newborns and infants, whose vascular systems are extremely small and delicate, may be at greater risk if the particulates are large enough to obstruct capillaries. Patients with pre-existing conditions affecting the lungs or heart may also experience more severe complications, such as inflammation or embolisms, if foreign matter enters their circulatory system.
It is important to note that the severity of the risk often depends on the size and quantity of the particulate matter present. While small particles might pass through without immediate harm, larger fragments can cause blockages in blood vessels, leading to tissue damage or infection. Since this is classified as a Class I recall by the FDA—the most serious category indicating that use of the product could cause serious adverse health consequences or death—the margin for error is virtually zero. Therefore, any patient receiving an IV from the affected lot J4H077 should be considered at significant risk until the fluid is verified as safe or replaced.
Finally, healthcare providers and nursing staff are indirectly at risk but play a crucial role in mitigating it. They are responsible for inspecting IV bags before administration and verifying lot numbers against recall lists. If you or a loved one is currently hospitalized, it is wise to ask your care team if the fluids being administered have been checked against recent FDA recalls, particularly those involving particulate contamination. While the statistical probability of harm from any single bag may be low, the potential impact on vulnerable patients makes this recall a serious matter requiring immediate attention from medical professionals rather than individual patients.
How to tell if you have the recalled item
If you are a healthcare professional or a patient managing an infusion at home, verifying whether your medication is part of this specific recall requires careful attention to several distinct identifiers on the packaging. Because Lactated Ringer's Injection is administered intravenously and is critical for fluid and electrolyte balance, mixing up product lines can be dangerous. B. Braun Medical, Inc., based in Bethlehem, Pennsylvania, has issued a Class I recall due to the presence of particulate matter in specific lots. To determine if your unit is affected, you must cross-reference multiple data points found directly on the primary container label and the outer shipping carton. Do not rely solely on the product name, as this solution is widely distributed under various lot numbers and expiration dates. You need to look for a precise combination of the National Drug Code (NDC), the specific Lot Number, and the expiration date to confirm if your item is included in this recall action. First, locate the primary container label on the 1000 mL EXCEL container. This is a prescription-only drug, meaning it is typically dispensed by pharmacies or administered directly in clinical settings. Look for the NDC number printed clearly on the label. For this specific recall event, the only affected NDC is 0264-7750-00. If your container bears a different NDC, it is not part of this particular recall notice, though you should always verify with your pharmacist or provider if you have any doubts about product authenticity. Next, turn your attention to the Lot Number. This alphanumeric code is crucial for tracing the manufacturing batch. The recalled lot number is J4H077. It is vital to check this number exactly; even a single digit difference means the unit was manufactured in a different batch and is not subject to this specific recall order. Finally, verify the expiration date printed on the label. The affected units in this recall have an expiration date of 30NOV2026. This date indicates when the product is no longer guaranteed to meet its labeled potency and sterility standards under normal storage conditions. If your container shows a different expiration date, it is not part of this recall. Please note that while the distribution pattern for this recall is nationwide across the United States, the manufacturer is B. Braun Medical, Inc., located at 18018-3524 USA in Bethlehem, PA. If you have an IV bag matching all three criteria—NDC 0264-7750-00, Lot J4H077, and Exp 30NOV2026—you must stop using it immediately. Do not attempt to clear particulate matter by filtering or shaking the container. Instead, contact your healthcare provider or the pharmacy that dispensed the medication to arrange for a replacement or proper disposal according to their specific protocols.What to do — step by step
If you are a healthcare professional or work in a facility that handles intravenous fluids, the first and most critical action you must take immediately is to stop using the recalled product. This is not a suggestion; it is a necessary safety protocol. The recall involves Lactated Ringer's Injection USP in 1000 mL EXCEL containers manufactured by B. Braun Medical, Inc. Specifically, this applies to units with National Drug Code (NDC) 0264-7750-00 and Lot number J4H077, which has an expiration date of November 30, 2026. The reason for this immediate cessation is the presence of particulate matter within the solution. In medical settings, introducing foreign particles into a patient’s bloodstream via intravenous injection can lead to serious complications, including blockages in small blood vessels, inflammation, or embolisms. Therefore, any remaining stock from this specific lot must be quarantined right away to prevent accidental administration.
Once you have secured the affected inventory, you need to verify exactly what you have in your possession. Check your storage areas, nursing stations, and pharmacy dispensing systems for the specific identifiers mentioned above. Look carefully at the labeling on the bags. You are looking for the NDC 0264-7750-00 printed clearly on the package, along with Lot number J4H077. It is vital to distinguish this lot from others produced by B. Braun Medical, Inc., as this recall is limited to this specific batch distributed nationwide. If you find bags matching these details, do not throw them in the regular trash or return them to general circulation. They must be kept separate and clearly marked as recalled product.
Because the official recall notice from the FDA does not specify a detailed remedy such as a direct consumer refund process or a prepaid return shipping label, your next steps depend entirely on your role in the supply chain. If you are a hospital, clinic, or pharmacy, you should contact B. Braun Medical, Inc., located in Bethlehem, PA, directly to report the inventory and inquire about their specific disposal or replacement procedures for healthcare providers. They may provide instructions on how to safely dispose of the particulate-contaminated units or arrange for credit. If you are a patient who has already received this product, you should contact your healthcare provider immediately to discuss any potential monitoring needed, though no adverse incidents have been reported yet. For general inquiries regarding this recall, you can reach B. Braun Medical, Inc. at their corporate headquarters in Bethlehem, PA 18018-3524 USA. Always prioritize communication with the manufacturer or your internal safety officer to ensure that all regulatory reporting requirements are met correctly and that no other patients are exposed to the hazard.
Your refund, repair, or replacement options
When a product recall occurs, the most immediate concern for consumers and healthcare providers alike is often: "What happens next?" In this specific case involving B. Braun Medical Inc.'s Lactated Ringer's Injection USP, the official FDA record provides a somewhat limited view of the remedy. The documentation does not explicitly detail a standard consumer-facing refund process, nor does it list a dedicated customer service hotline or online portal for returns. Instead, because this is a Class I recall involving a prescription-only intravenous fluid distributed through professional medical channels, the "remedy" is structured differently than it would be for a retail toy or appliance. Understanding how this works requires looking at who handles these products and how the supply chain operates.
First, it is important to clarify that Lactated Ringer's Injection is not a product typically purchased by individuals for home use. It is a prescription medication (Rx only) used in hospitals, clinics, and emergency rooms. Therefore, the "refund" or "replacement" process is not something you will initiate by calling a general consumer support line. Instead, the remedy is managed through the professional distribution network. If you are a patient who has already received this specific lot, your healthcare provider is responsible for managing the clinical aspect of the recall. They will assess whether the administered fluid poses any risk and determine if any medical intervention is necessary. You do not need to contact B. Braun directly as an individual consumer; that communication is reserved for the facilities and distributors who purchased the units.
For the healthcare facilities, pharmacies, or distributors that still possess inventory of NDC 0264-7750-00, Lot J4H077, the remedy involves ceasing use immediately. While the specific instructions for returning the physical containers are not detailed in this summary, Class I recalls typically require the strictest level of cooperation from the supply chain. The manufacturer, B. Braun Medical, Inc., located in Bethlehem, PA, is expected to coordinate with its national distribution partners to ensure these units are pulled from shelves and storage areas. If you are a medical professional or facility manager, you should refer to the official FDA recall press release or contact your regional B. Braun sales representative for specific return authorization procedures. They will guide you on how to safely dispose of or return the affected EXCEL containers.
If you are a patient who is concerned about having received this product, do not attempt to return it yourself. Intravenous fluids are hazardous waste and cannot be returned through standard mail or retail channels. Instead, focus on your health. If you have been treated with Lactated Ringer's from this lot within the last several months, contact your doctor or the hospital where you received care. Inform them that you were administered product from Lot J4H077, which expired on November 30, 2026. They will check their records and monitor you for any potential effects related to particulate matter exposure. Your "option" in this scenario is primarily one of vigilance and communication with your care team, rather than a financial transaction or product exchange.
In summary, while the recall does not offer a simple consumer refund process, it does trigger a rigorous professional response. The remedy relies on the immediate cessation of use by healthcare providers and the monitoring of patients who may have been exposed. There is no public-facing repair or replacement program for individual consumers because this product is strictly part of the medical supply chain. Your best course of action is to ensure your healthcare provider is aware of the recall details so they can manage any necessary follow-up care for you.
What can happen if you ignore it
When a Class I recall is issued by the FDA, it signals the highest level of urgency because the situation poses a serious threat to health or death. In this specific case involving B. Braun Medical Inc.’s Lactated Ringer’s Injection, the hazard is the presence of particulate matter within the 1000 mL EXCEL container. It is crucial to understand that you are not dealing with a defective label or a minor packaging error; you are potentially handling fluid that contains foreign particles. If you continue to use this product or fail to alert your healthcare provider immediately, the consequences can be severe and irreversible. The primary danger lies in what happens when these particulates enter the bloodstream. Lactated Ringer’s is an intravenous (IV) solution designed to flow directly into your veins to restore fluid balance, correct electrolyte imbalances, or serve as a vehicle for other medications. The body’s vascular system is delicate. While small amounts of microscopic particles might sometimes be filtered by the lungs without immediate catastrophic failure, larger or numerous particulates can cause mechanical blockages. This phenomenon, known as embolism, occurs when these foreign objects travel through the blood and lodge in smaller vessels. If this happens in the lungs (pulmonary embolism), it can impair oxygen exchange, leading to shortness of breath, chest pain, and potentially respiratory failure. In more severe cases, if particles bypass the pulmonary filter or originate from a central line, they can travel to the brain or heart, causing strokes, heart attacks, or permanent tissue damage. Beyond immediate blockages, particulate matter can trigger intense inflammatory responses. The immune system recognizes these foreign bodies as invaders and may launch an aggressive attack, leading to phlebitis (inflammation of the vein), fever, or systemic inflammation. For patients who are already critically ill, elderly, or have compromised immune systems, this added stress can tip the balance from recovery to critical decline. There is also the risk of infection. Although B. Braun is a reputable manufacturer and sterile manufacturing processes are rigorous, the presence of particulate matter often indicates a breach in that sterility or a failure in the filtration process during production. This breach could potentially introduce bacteria or other pathogens into the solution, leading to bloodstream infections (sepsis), which are life-threatening emergencies requiring intensive care. It is important to note that while this recall was announced on August 12, 2026, and involves Lot J4H077 expiring in November 2026, the risk does not vanish because the product looks normal. The particles are likely invisible to the naked eye within the clear fluid. Ignoring the recall means gambling with your vascular health. You might feel fine initially, but microscopic damage can accumulate. By ignoring this alert, you are allowing a known, serious hazard to remain in your care pathway. The consequence is not just a potential allergic reaction or minor irritation; it is the risk of embolization, organ damage, severe inflammatory response, and potentially death. In a medical context, there is no "wait and see" approach when Class I particulate contamination is involved. The only safe path is immediate cessation and professional evaluation.Staying safe: broader tips
When we talk about medical products like intravenous fluids, the term "safety" often brings to mind rigorous manufacturing standards and strict regulatory oversight. While those are absolutely essential, there is a practical layer of safety that falls on healthcare providers and patients to manage daily. Because recalls, no matter how rare or well-managed, are part of the landscape of modern medicine, staying informed and proactive is your best defense against unexpected complications. The most powerful tool you have is knowledge of where to look for official updates. Instead of waiting for a notification that might get lost in a busy inbox, make it a habit to visit the U.S. Food and Drug Administration (FDA) website directly. They maintain a dedicated recall database that is searchable by company name, product type, or hazard. Bookmarking this resource and checking it periodically can help you stay ahead of potential issues before they reach your local pharmacy or hospital supply chain.
For healthcare professionals and patients alike, understanding the importance of lot tracking is critical. In the event of a safety alert, the ability to quickly identify specific batches of medication can mean the difference between a minor logistical hiccup and a serious health crisis. Always ensure that your medical records and pharmacy receipts clearly display the National Drug Code (NDC) and the lot number of any prescription drugs or medical supplies you use. This information is not just administrative data; it is the key to verifying the safety status of every item entering your body. If you are a caregiver, consider keeping a simple log of high-risk medications, noting the dates they were administered and their specific batch numbers. This practice does not require advanced technical skills, but it provides a crucial layer of accountability and traceability that can save lives during an emergency.
Beyond tracking specific items, fostering open communication within your healthcare team is vital. Never hesitate to ask questions about the products being used in your care. If you notice any unusual appearance in a medication—such as cloudiness, discoloration, or visible particles—do not assume it is normal. Report it immediately to the administering nurse or pharmacist. While most variations are harmless, vigilance regarding particulate matter in IV fluids is especially important, as these tiny fragments can potentially block small blood vessels if they enter the bloodstream. By combining official monitoring resources with personal diligence and clear communication, you create a robust safety net that protects you beyond any single recall event.
- Regularly check the FDA’s Recall Database for updates on products you use frequently.
- Keep detailed records of lot numbers for all critical medications and medical devices.
- Inspect all IV fluids and injectables for clarity before administration; report any anomalies immediately.